Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Esther J. Beck; Alexander D. Sherry; Marcus A. Florez; Ramez Kouzy; Joseph Abi Jaoude; Timothy A. Lin; Avital M. Miller; Adina H. Passy; Gabrielle S. Kupferman; Roshal R. Patel; Fumiko Chino; Victoria Serpas Higbie; Christine M. Parseghian; Michael J. Overman; Bruce D. Minsky; Charles R. Thomas; Chad Tang; Pavlos Msaouel; Ethan B. Ludmir

doi:10.1158/2767-9764.27101873

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Comparison of publication and reporting between the overall dataset and the sensitivity analysis restricting SEPs to only those from both the protocol and ClinicalTrials.Gov, from trials with multiple protocols available.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beck et al. (2024) studied this question.

synapsesocial.com/papers/68e5778bb6db643587517192 https://doi.org/10.1158/2767-9764.27101873

View at Publisher

Ask AI

Bookmark

Share

Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Ask about this paper

Abstract

Discussion

Cite This Study

Supplemental Table S6 from Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading